32. Benedetti, S., et al., The effects of Acyclovir administration to NCI-H1975 non-small cell lung cancer cells. Toxicol In Vitro, 2022. 79: p. 105301.
33. Özdemir, M.D. and D. Göktürk, The concurrent effect of acyclovir and rosemary on glioblastoma cell culture. Cell Mol Biol (Noisy-le-grand), 2019. 65 (3): p. 66-71.
34. Asano-Mori, Y., et al., Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation. Int J Hematol, 2008. 87 (3): p. 310-8.
35. Asahi, T., et al., Valacyclovir neurotoxicity: clinical experience and review of the literature. Eur J Neurol, 2009.16 (4): p. 457-60.
36. Yu, R.J., et al., Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS). J Allergy Clin Immunol Pract, 2021.9 (2): p. 819-829.e2.
37. Golomb, B.A., et al., Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Drug Saf, 2007. 30 (8): p. 669-75.
38. Hazell, L. and S.A. Shakir, Under-reporting of adverse drug reactions : a systematic review. Drug Saf, 2006. 29 (5): p. 385-96.